AR112192A1 - Compuestos de azaindol como inhibidores de histona metiltransferasa - Google Patents
Compuestos de azaindol como inhibidores de histona metiltransferasaInfo
- Publication number
- AR112192A1 AR112192A1 ARP180101557A AR112192A1 AR 112192 A1 AR112192 A1 AR 112192A1 AR P180101557 A ARP180101557 A AR P180101557A AR 112192 A1 AR112192 A1 AR 112192A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkoxy
- haloalkyl
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), en donde: X es N o CR¹; Y es N o CR²; P, Q, T y U son independientemente CH, C (cuando se une R⁴ o R⁵), o N; siempre que al menos uno y no más que dos de P, Q, T y U sean N; Z es O, S, o NR⁶, en donde R⁶ es hidrógeno, alquilo o cicloalquilo; R¹ es hidrógeno, alquilo, alcoxi, halo, haloalquilo, haloalcoxi o cicloalquilo; R² es hidrógeno, alquilo, alcoxi, halo, haloalquilo, haloalcoxi o cicloalquilo; R³ es -W-alquileno-R⁷, en donde: W es un enlace, NH, O ó S; alquileno se sustituye opcionalmente con R⁸, en donde R⁸ es halo, haloalquilo, haloalcoxi, hidroxi o alcoxi, y un CH₂ en el alquileno se remplaza opcionalmente con NH u O; y R⁷ es -NRᵃRᵇ, en donde Rᵃ y Rᵇ son independientemente hidrógeno, alquilo o haloalquilo; o Rᵃ y Rᵇ junto con el nitrógeno al cual se unen, forman heterocicloamino, heterocicloamino puenteado o espiroheterocicloamino, en donde el heterocicloamino, el heterocicloamino puenteado y el espiroheterocicloamino se sustituyen opcionalmente con uno o dos sustituyentes que se seleccionan independientemente de alquilo, halo, haloalquilo, hidroxi, alcoxi y haloalcoxi; o R⁷ es heterociclilo que se une al alquileno en un átomo de carbono de anillo y se sustituye opcionalmente con uno o dos sustituyentes que se seleccionan independientemente de alquilo, halo, haloalquilo, hidroxi, alcoxi y haloalcoxi; R⁴ y R⁵ son independientemente alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, halo, hidroxi, haloalcoxi, alcoxi, ciano, NH₂, NRᶜRᵈ, alcoxialquilamino, hidroxialquilamino, aminoalquilamino, hidroxialquilo, alcoxialquilo, alquiltio, alcoxialquiloxi, fenilo, heteroarilo, heteroariloxi, heterociclilo, heterocicliloxi, heterociclilamino, heterocicloamino o espiroheterocicloamino puenteados de 5 - 8 miembros, en donde el fenilo, el cicloalquilo, el heteroarilo y el heterociclilo, ya sea solos o como parte de otro grupo, se sustituyen opcionalmente con uno, dos o tres sustituyentes que se seleccionan independientemente de alquilo, halo, haloalquilo, haloalcoxi, hidroxi, hidroxialquilo, alcoxi, NH₂, alquilamino, dialquilamino, carboxi, carboxialquilo y alcoxicarbonilo y en donde el alquilo de R⁴ y R⁵ se sustituye opcionalmente con cicloalquilo y opcionalmente el alquenilo y el alquinilo de R⁴ y R⁵ se sustituyen independientemente con hidroxi o cicloalquilo; Rᶜ es hidrógeno, alquilo, cicloalquilo o heterociclilo; Rᵈ es alquilo, cicloalquilo o heterociclilo; o Rᶜ y Rᵈ, junto con el nitrógeno al cual se unen, forman un heterocicloamino de 4 a 7 miembros; y v y w son independientemente 0 ó 1; o una sal farmacéuticamente aceptable de estos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762517410P | 2017-06-09 | 2017-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112192A1 true AR112192A1 (es) | 2019-10-02 |
Family
ID=62779058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101557 AR112192A1 (es) | 2017-06-09 | 2018-06-08 | Compuestos de azaindol como inhibidores de histona metiltransferasa |
Country Status (11)
Country | Link |
---|---|
US (2) | US11111243B2 (es) |
EP (1) | EP3634962B1 (es) |
JP (1) | JP7225125B2 (es) |
CN (1) | CN110997671A (es) |
AR (1) | AR112192A1 (es) |
BR (1) | BR112019025770A2 (es) |
ES (1) | ES2949402T3 (es) |
IL (1) | IL271066A (es) |
MX (1) | MX2019014759A (es) |
TW (1) | TW201920165A (es) |
WO (1) | WO2018226998A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3634962B1 (en) * | 2017-06-09 | 2023-05-24 | Global Blood Therapeutics, Inc. | Azaindole compounds as histone methyltransferase inhibitors |
CN114394971B (zh) * | 2022-01-24 | 2023-01-31 | 云南大学 | 一种吲哚咔唑类化合物的制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
HUP0300894A3 (en) | 2000-03-15 | 2008-05-28 | Sanofi Aventis Deutschland | Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use |
WO2008055233A1 (en) * | 2006-10-31 | 2008-05-08 | Supergen, Inc. | Protein kinase inhibitors |
UA109896C2 (xx) | 2007-02-22 | 2015-10-26 | Похідні імінопіридину та їх застосування як мікробіоцидів | |
WO2009085185A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
DK2364983T3 (da) | 2008-11-11 | 2013-12-09 | Jeil Pharmaceutical Co Ltd | Nyt tricyklisk derivat eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende disse |
IL302896A (en) * | 2009-10-06 | 2023-07-01 | Millennium Pharm Inc | Heterocyclic compounds used as PDK1 inhibitors |
US20130231360A1 (en) * | 2010-04-22 | 2013-09-05 | The Brigham And Women S Hospital, Inc. | Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases |
CA2803697A1 (en) * | 2010-06-25 | 2011-12-29 | Facultes Universitaires Notre Dame De La Paix | Beta carboline derivatives useful in the treatment of proliferative disorders |
TW201236880A (en) | 2011-03-11 | 2012-09-16 | Primax Electronics Ltd | Sheet feeding apparatus |
EP2688887B1 (en) | 2011-03-23 | 2015-05-13 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
US10662193B2 (en) | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
US9284272B2 (en) | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
EP3154957B1 (en) | 2014-06-16 | 2019-11-20 | Fundacion para la Investigacion Medica Aplicada | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases |
EP3377490A1 (en) | 2015-11-16 | 2018-09-26 | Fundacion para la Investigacion Medica Aplicada | Novel compounds as inhibitors of dna methyltransferases |
EP3634962B1 (en) * | 2017-06-09 | 2023-05-24 | Global Blood Therapeutics, Inc. | Azaindole compounds as histone methyltransferase inhibitors |
-
2018
- 2018-06-07 EP EP18735073.1A patent/EP3634962B1/en active Active
- 2018-06-07 JP JP2019567574A patent/JP7225125B2/ja active Active
- 2018-06-07 MX MX2019014759A patent/MX2019014759A/es unknown
- 2018-06-07 US US16/002,408 patent/US11111243B2/en active Active
- 2018-06-07 ES ES18735073T patent/ES2949402T3/es active Active
- 2018-06-07 BR BR112019025770-5A patent/BR112019025770A2/pt not_active Application Discontinuation
- 2018-06-07 WO PCT/US2018/036521 patent/WO2018226998A1/en active Application Filing
- 2018-06-07 CN CN201880050882.9A patent/CN110997671A/zh active Pending
- 2018-06-08 TW TW107119935A patent/TW201920165A/zh unknown
- 2018-06-08 AR ARP180101557 patent/AR112192A1/es unknown
-
2019
- 2019-12-01 IL IL271066A patent/IL271066A/en unknown
-
2021
- 2021-08-06 US US17/396,312 patent/US20210371417A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110997671A (zh) | 2020-04-10 |
US20210371417A1 (en) | 2021-12-02 |
BR112019025770A2 (pt) | 2020-06-23 |
EP3634962A1 (en) | 2020-04-15 |
ES2949402T3 (es) | 2023-09-28 |
US20180354947A1 (en) | 2018-12-13 |
IL271066A (en) | 2020-01-30 |
JP2020523315A (ja) | 2020-08-06 |
WO2018226998A1 (en) | 2018-12-13 |
JP7225125B2 (ja) | 2023-02-20 |
EP3634962B1 (en) | 2023-05-24 |
US11111243B2 (en) | 2021-09-07 |
MX2019014759A (es) | 2020-02-12 |
TW201920165A (zh) | 2019-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
AR113965A1 (es) | Triazol azoles ciclohexil ácidos como antagonistas de lpa | |
AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
AR108130A1 (es) | Derivados de pirazolopirimidina | |
AR113929A1 (es) | Compuestos heterocíclicos | |
AR110405A1 (es) | Compuestos | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
PE20211779A1 (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
AR110753A1 (es) | Inhibidores selectivos de jak1 | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |